| 1 |
Wang W, Chen Y, Wu L, Zhang Y, Yoo S, Chen Q, Liu S, Hou Y, Chen XP, Chen Q, Zhu J. HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC). BMC Med Genomics 2022;15:134. [PMID: 35710421 DOI: 10.1186/s12920-022-01264-2] [Reference Citation Analysis]
|
| 2 |
Wang H, Davido DJ, Mostafa HH, Morrison LA. Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication. Viruses 2022;14:869. [DOI: 10.3390/v14050869] [Reference Citation Analysis]
|
| 3 |
Carr DJJ, Berube A, Gershburg E. The Durability of Vaccine Efficacy against Ocular HSV-1 Infection Using ICP0 Mutants 0∆NLS and 0∆RING Is Lost over Time. Pathogens 2021;10. [PMID: 34832625 DOI: 10.3390/pathogens10111470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Carr DJJ, Berube AN, Filiberti A, Gmyrek GB. Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0ΔNLS vaccine against ocular HSV-1 challenge. Vaccine 2021;39:2526-36. [PMID: 33814229 DOI: 10.1016/j.vaccine.2021.03.075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 5 |
Gmyrek GB, Filiberti A, Montgomery M, Chitrakar A, Royer DJ, Carr DJJ. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice. J Virol 2020;94:e01000-20. [PMID: 32999018 DOI: 10.1128/JVI.01000-20] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 6 |
Carr DJJ, Gmyrek GB, Filiberti A, Berube AN, Browne WP, Gudgel BM, Sjoelund VH. Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1-Encoded Proteins. Immunohorizons 2020;4:608-26. [PMID: 33037098 DOI: 10.4049/immunohorizons.2000060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 7 |
Ramsey NLM, Visciano M, Hunte R, Loh LN, Burn Aschner C, Jacobs WR Jr, Herold BC. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus. J Virol 2020;94:e00335-20. [PMID: 32295919 DOI: 10.1128/JVI.00335-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 8 |
Ike AC, Onu CJ, Ononugbo CM, Reward EE, Muo SO. Immune Response to Herpes Simplex Virus Infection and Vaccine Development. Vaccines (Basel) 2020;8:E302. [PMID: 32545507 DOI: 10.3390/vaccines8020302] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 9 |
Poccardi N, Rousseau A, Haigh O, Takissian J, Naas T, Deback C, Trouillaud L, Issa M, Roubille S, Juillard F, Efstathiou S, Lomonte P, Labetoulle M. Herpes Simplex Virus 1 Replication, Ocular Disease, and Reactivations from Latency Are Restricted Unilaterally after Inoculation of Virus into the Lip. J Virol 2019;93:e01586-19. [PMID: 31554680 DOI: 10.1128/JVI.01586-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
